Abstract
Microfluidic technology (MF) has improved the formulation of nanoparticles (NPs) by achieving uniform particle size distribution, controllable particle size, and consistency. Moreover, because liquid mixing can be precisely controlled in the pores of the microfluidic chip, maintaining high mixing efficiency, MF exerts higher of NP encapsulation efficiency (EE) than conventional methods. MF-NPs-cabazitaxel (CTX) particles (MF-NPs-CTX) were first prepared by encapsulating CTX according to MF. Folate (FA)- Polyethylene glycol (PEG)-NPs-CTX particles (FA-PEG-NPs-CTX) were formulated by connecting FA to MF-NPs-CTX to endow NPs with targeted delivery capability. Accordingly, the mean particle size of FA-PEG-NPs-CTX increased by approximately 25 nm, as compared with MF-NPs-CTX. Upon morphological observation of FA-PEG-NPs-CTX and MF-NPs-CTX by transmission electron microscopy (TEM), all NPs were spherical and particle size distribution was uniform. Moreover, the increased delivery efficiency of CTX in vitro and its strong tumor inhibition in vivo indicated that FA-PEG-NPs-CTX had a powerful tumor-suppressive effect both in vitro and in vivo. In vivo imaging and pharmacokinetic data confirmed that FA-PEG-NPs-CTX had good drug delivery efficiency. Taken together, FA-PEG-NPs-CTX particles prepared using MF showed high efficient and targeted drug delivery and may have a considerable driving effect on the clinical application of targeting albumin NPs.
Highlights
After the Food and Drug Administration (FDA) approved Abraxane (Abraxis BioScience, Los Angeles, CA, USA) in 2010, albumin NPs have increasingly been attracting researchers’ attention [1].Nano-formulation delivery systems have been widely used because of their unique biocompatibility and stability [2]
Within 48 h, the average particle size was increased by about 30 nm. These results indicate that Microfluidic technology (MF)-NPs-CTX and FA-Polyethylene glycol (PEG)-NPs-CTX had good stability in serum
Within 48 h, the average particle size was by about 30 nm
Summary
After the Food and Drug Administration (FDA) approved Abraxane (Abraxis BioScience, Los Angeles, CA, USA) in 2010, albumin NPs have increasingly been attracting researchers’ attention [1]. Nano-formulation delivery systems have been widely used because of their unique biocompatibility and stability [2]. Sufficient drug binding sites are contained in human serum albumin (HSA). Molecules, endowing albumin NPs with a high drug-loading capacity [3,4,5]. Cancers 2019, 11, 1571 and stability [2]. Sufficient drug binding sites are contained in human serum albumin (HSA) molecules, endowing albumin NPs with a high drug-loading capacity [3,4,5]. Albumin exploitedtotodeliver delivervarious various drugs, such as antineoplastic agents, AlbuminNPs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
